Biocompatible PAMAM‐PLGA‐PCL Nanocarrier for Efficient Curcumin Delivery to Lung Cancer Cells: In Vitro Studies

Abstract

AbstractLung cancer, as the leading cause of death among other types of cancer, has a high rate of incidence throughout the world. Although conventional modalities, like chemotherapy, have been applied for the inhibition of this cancer, they have not led to the suppression of lung cancer owing to their deficiencies. Thus, we developed a novel polylactic‐co‐glycolic acid (PLGA)‐polyamidoamine G4 (PAMAM G4)‐polycaprolactone (PCL) nanocarrier for efficient delivery of curcumin (Cur) to A549 lung cancer cells. The synthesized nanocarrier was characterized by applying analytical techniques, FT‐IR, DLS, TEM, and TGA. Successful synthesis, nano‐size diameter (40–80 nm), near neutral surface charge (8.0 mV), and high drug entrapment (11.5 %) were measured for the nanocarrier. Controlled (about 5 folds within first 2 h) and pH‐sensitive (2–3 folds faster within first hours) Cur release observed for PLGA‐PAMAM‐PCL‐Cur. Cell viability test (MTT assay) indicated the high capability of nanocarrier in suppression of A549 cancer cells (21 % viability after 24 h of treatment with 200 nM) while did not result in toxicity on MSC normal cells. The IC50 observed for 50 nM at 24 h of post‐treatment in A549 cells. The qRT‐PCR technique indicated inducing the expression of apoptotic genes (Caspase9 and Bax) by 6–8 folds and suppressing anti‐apoptotic gene (Bcl2) by 7 folds. ROS considerably increased in cancer cells as well. This nanocarrier would be a promising drug delivery system against lung cancer.